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Abstract 
 
Purpose: To determine pharmacists’ knowledge of legal highs (novel psychoactive 
substances; NPS). 
Approach: A questionnaire was handed out at 2 London pharmacist continuing education 
events in mid-2014. These events update pharmacists about developments of 
interest/relevance to the profession and to improve their practice. A total of 54 forms were 
returned; a response rate of 26%. 
Findings: Most pharmacists had poor knowledge of NPS and many considered that NPS were 
not important to their work, with few having had to advise customers in this area. Despite 
this, the majority thought that they had insufficient information about NPS. There was a 
negative correlation between the age of the pharmacist and knowledge of NPS. 
Research Limitations: The sample is a self-selected one drawn from registered pharmacists 
working in community pharmacies in North West London, and thus does not include 
hospital pharmacies. Self-selection means that respondents may only reflect those who are 
interested in the NPS phenomenon and not the wider pharmacy community. The 
geographical area covered may not be representative of London as a whole, or indeed other 
parts of the UK or other EU countries. 
Practical and Social Implications: It is clear that pharmacists do not know much about NPS 
but would like to know more. This information might improve their practice. Pharmacists, 
easier to see than general practitioners, could be a useful source of information for NPS 
misusers. 
Originality: There have been no previous attempts to gauge the level of knowledge by 
pharmacists of legal highs/novel psychoactive substances  in the UK or elsewhere to our 
knowledge. 
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Introduction 
 
Legal highs is the common term for a collection of drugs, many of which are new, or are 
older drugs, now misused [1, 2]. There is debate around nomenclature and definition [3], but 
within Europe most researchers use the term novel psychoactive substance (NPS), using the 
definition of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)[4]. 
Over the last 5-10 years there has been a steady increase in the number of NPS[5] with 
approximately 100 new NPS found in 2013. There are also increasing numbers of deaths 
associated with legal high use[6], although in most cases the deceased are polydrug 
misusers and the drug(s) which caused death cannot be accurately determined.  Despite 
this, and the increased media attention, many healthcare professionals know little about 
NPS, and there are few studies describing their pharmacology or toxicity, mephedrone being 
a notable exception. With anticipated increases in NPS use and consequent public health 
issues, there is a need to educate healthcare professionals about NPS.  
 
In the UK, the Pharmacy profession is moving towards a more front-line position, where 
patients may come to see a pharmacist about a problem instead of visiting their general 
practitioner (GP). It is anticipated that this will increasingly become the case with a 
predicted reduction in UK GP services, and prescribing pharmacists becoming more 
common. The role of the pharmacists in prescription drug misuse is acknowledged[7]. Despite 
this, the Pharmacy curriculum, at least in the UK, does not typically place much emphasis 
on drug misuse and almost nothing is taught regarding NPS. The UK General Pharmaceutical 
Council, in its 2011 ‘Future Pharmacists’[8] document briefly mentions drug misuse, but 
there is no mention of NPS.  Thus, education on substance use and misuse targeting 
pharmacists and the pharmacy team is very limited. Two optional short courses ‘Substance 
use and misuse’ and ‘Addiction, misuse and dependency’ have been developed by the 
Centre for Pharmacy Postgraduate Education (CPPE) in order to prevent the misuse of over-
the-counter (OTC), prescription medicines and traditional drugs of abuse such as cocaine 
and heroin. These courses aim to equip pharmacists to identify groups of patients who may 
misuse OTC or prescription medicines and learn about the pharmaceutical interventions 
that could be undertaken. These courses do not include information on NPS[9-10].  
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We can thus foresee a time in the near future where more and more pharmacists will be 
asked about NPS by their patients, with pharmacists not having appropriate knowledge to 
answer them. This pilot study was designed to gauge UK pharmacists’ knowledge of NPS 
with a view to designing appropriate educational resources for pharmacists and related 
healthcare professionals. 
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Methods  
 
Questionnaire. The survey was based on an existing questionnaire used for a previous EU-
funded project (RedNet; http://www.rednetproject.eu) and contained a brief definition of 
NPS and the categories used by the EMCDDA. The survey first asked for some demographic 
data (e.g. sex, age, years of pharmacy practise) then asked about knowledge of NPS. We 
then listed 38 relatively well known NPS and asked subjects if they had heard of them. 
Finally we asked about what type of information they would like about NPS and whether it 
was important to their pharmacy practice. 
 
Administration of questionnaire. The questionnaire was distributed at 2 London North West 
Local Practice Forum continuing professional development events in mid-2014 (207 
attendees). These events update pharmacists about developments of interest/relevance to 
the profession and to improve their practice. One of the authors (AG) spoke about our EU-
funded EU-MADNESS project (http://www.eumadness.eu) and that one of its aims is to 
establish current levels of knowledge amongst healthcare professionals. The paper 
questionnaire was distributed to all attendees. A total of 54 forms was returned; a response 
rate of 26%. Usually, each attendee represents a different community pharmacy. Ethics 
approval was granted by the University of Hertfordshire Health & Human Sciences ECDA; 
protocol number aPHAEC1042(03). 
 
Statistics. Data were collated and graphed using SigmaPlot. Spearman correlation analysis 
was performed on age of pharmacist versus number of NPS of which they were aware. Fig 2 
was analysed by a Kruskal-Wallis 1-way ANOVA on ranks, multiple comparisons were made 
using Dunn’s Method and the data plotted are the medians. 
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Results 
 
Participants. Of the 54 respondents there were 32 female (59%) and 22 male (41%).  Most 
considered that they had ‘poor’ to ‘basic’ knowledge of NPS (40 pharmacists; 74%; Fig 1A) 
and most (29; 54%) did not provide advice or counselling to patients or customers on NPS, 
while only 8 (15%) said that they did provide counselling on NPS (Fig 1B).  
 
Knowledge of NPS. Of 36 relatively common NPS we listed, 16 (30%) pharmacists were not 
aware that any were being misused, while 11 (20%) were only aware that 1 was being 
misused (Fig 1C). The most commonly recognised misused drugs were pregabalin 
(recognised by 32 pharmacists; 59%), mephedrone (17; 31%), benzydamine (13; 25%), 
tropicamide (9; 18%) and ‘Spice’ (9; 18%). There was a negative correlation between the age 
of the pharmacist and the number of NPS that they had heard of (p < 0.01, Pearson’s 
correlation; Fig 1D). 
 
Relevance of NPS to Pharmacy and future learning needs. Although 20 pharmacists (20; 
37%) thought that knowledge of NPS had ‘little’ significance to their work (Fig 1E), the 
overwhelming majority (50; 93%) thought that they did not have enough information about 
NPS. Most got their information from the internet/web (21, 39%), followed by the media 
(15; 28%), seminars (12; 22%) and email (11; 20%; Fig 1F). The majority wanted to be 
updated about NPS (44; 81%) with only 8 (15%) stating that they did not want to be 
updated. Their preferred method for being updated was by email (38; 70%), followed by the 
Internet/Web (25; 46%) and online courses (19; 35%). 
 
When asked about the type of information that they wanted, to improve their knowledge 
of NPS, it was found that knowledge of NPS adverse events, clinical warnings and desired 
psychoactive effects were considered most significant, all 3 were rated higher compared 
to knowledge of chemical characterisation of NPS (H (12) =24.04, P < 0.05; Fig 2).  
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Discussion 
 
These pilot data suggest that although knowledge of NPS may not have been considered 
central to a pharmacist’s job, with few pharmacists offering advice on NPS to customers or 
patients, there is an acknowledgement that information on this area is needed. 
 
Of the 36 relatively common NPS listed in the survey, pregabalin was the most well-known 
misused drug. This is unsurprising as it is prescribed for neuropathic pain, anxiety and 
epilepsy, is misused[11] and is increasingly associated with drug-related deaths[6]. Of the 
other well-recognised NPS, benzydamine is found in oral rinses for sore throats and 
tropicamide is used to dilate the pupil in diagnostic eye test; both these drugs are 
misused[12, 13]. Thus the number of genuinely ‘novel’ psychoactive substance known by 
pharmacists is small, with the stimulant mephedrone and the synthetic cannabinoid ‘Spice’ 
drugs the best known. This confirms that pharmacists in London have a poor knowledge of 
NPS. 
The re-emergence and abuse of older clinically used/tested drugs is not a new 
phenomenon, but appears to be gathering pace. There are increasing numbers of old 
disused clinical drugs being rebranded by Internet opportunists as legal highs. For example, 
desoxypipradrol, tested for narcolepsy many decades ago, resurfaced in 2009 as ‘Ivory 
Wave’ and was associated with a number of drug related deaths[14]. In addition, alpha-
methyltryptamine (AMT), once used as an antidepressant, is also now misused[15] and 
associated with drug-related deaths[6]. It should be noted that in most cases the exact 
cause of death is not known because multiple drugs, including alcohol and nicotine, are 
typically taken by drug misusers. The multiple online user forums are full of user reports 
specifying which drug combinations have been taken to obtain the psychological changes 
sought, and also drug(s) taken to ease the comedown, facilitate sleep or reduce 
withdrawal effects. 
In the UK, pharmacists are leading health care professionals in the different health care 
settings. In primary care, it was reported that more than 1.4 million people visit 11,500 
community pharmacies on the high streets every day in England. This makes pharmacists 
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very well suited to reach out to customers or patients who may have or may be developing 
substance misuse[16]. Pharmacists are equipped with the knowledge and skills to promote 
education, detection, prevention and treatment of drug misuse[17]. In 2010, pharmacists 
were formally notified of the health harms related to a new ‘legal high’ called ‘Ivory Wave’. 
With the limited knowledge provided then, pharmacists were able to raise awareness and 
educate customers on the potential toxicities that may result from the intake of this 
substance[18]. 
 
Within their profession, pharmacists are involved in the provision of opiate substitute 
therapy and in the prescribing of controlled drugs for the treatment of many conditions 
including addiction[19]. In 2012, amendments to the UK Misuse of Drugs regulations (2001) 
were introduced and involved lifting restrictions and allowing independent pharmacist 
prescribers to prescribe any controlled drugs (Schedules 2-5) including diamorphine, 
dipipanone and cocaine for relieving pain but not for the treatment of addiction[20]. In 
secondary care, substance abuse is sometimes associated with psychiatric patients. Mental 
health pharmacists are commonly part of the multi-disciplinary team and are well equipped 
to provide pharmacological advice and to carry out pharmaceutical interventions in cases 
related to drug misuse[21, 22]. Assessment of complications/ toxicities related to substance 
misuse is often mutually assessed by the diagnosing doctors and pharmacists on psychiatric 
inpatient wards[21]. Available hospital guidelines commonly involve generic pharmaceutical 
interventions for the misuse of traditional stimulants, benzodiazepines, amphetamine and 
opiates in a manner, where ‘one size fits all’[21].  
 
In line with the UK national policy priorities in 2014, the care quality commission (CQC), the 
independent regulator of health and social care in England, has initiated pilot inspections 
of substance misuse services, which include services provided by pharmacists in inpatient 
units[22]. The substance misuse services currently provided do not include NPS related 
services. 
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Our data suggest that UK pharmacists will need further education on NPS either within 
the undergraduate curriculum or as part of their continuing professional development 
(CPD). We are currently funded by the EU MADNESS project, part of which is to create 
new learning resources for healthcare professionals. Our current studies include a survey 
of European Medical and Pharmacy schools, to determine what is being taught about NPS 
across Europe. We are also surveying undergraduate students in the UK to determine 
what they know about NPS and particularly if they believe them to be safe. Finally we 
have a larger UK-wide survey underway determining pharmacists’ knowledge of NPS. 
These data, taken with the current study will inform us of what type of information is 
needed to educate learners and teachers about NPS. To this end we will create specific 
PowerPoint slides and fact sheets on NPS specifically for pharmacists, as well as other 
healthcare professional.  
 
This study has some limitations. The sample is a self-selected one drawn from registered 
pharmacists working in community pharmacies in North West London, and thus does not 
include hospital pharmacies. Self-selection means that respondents may only reflect those 
who are interested in the NPS phenomenon and not the wider pharmacy community. The 
geographical area covered may not be representative of London as a whole, or indeed other 
parts of the UK or other EU countries. Despite this, it is clear that London pharmacists do 
not know much about NPS but would like to know more. 
Conclusions  
In conclusion, pharmacy education involving knowledge on NPS health harms, potential 
pharmaceutical interventions and referral pathways is lacking. Education related to NPS 
would enable pharmacists to contribute in recognising the local needs and in promoting 
prevention and education, which in turn would reduce the negative social impact of NPS 
misuse, unnecessary hospital admissions and avoidable fatalities. Pharmacists need 
further information on NPS, not only those prescription drugs which are now being misused 
but especially the new ‘designer’ NPS. In particular, pharmacists requested information 
related to the pharmacology and toxicity of NPS. 
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Figure 1. Results from a survey of London pharmacists on legal highs/NPS. A. most 
pharmacists considered that they had only a ‘poor’ or ‘basic’ knowledge of NPS. B. Most 
pharmacists did not help customers or patients with advice on NPS. C. Many pharmacists 
(28/54; 52%) were not aware that any, or only 1, of the 36 relatively common NPS listed in 
the survey, were being misused. 19/54 (35%) pharmacists were aware that 3 or more of the 
NPS listed were being misused. D. There was a negative correlation between the age of the 
pharmacist and the number of NPS that they were aware of. E. Many pharmacists thought 
that knowledge of NPS had little significance to their work (20/54; 37%) but nearly as many 
thought that it was ‘fairly’ significant (16/54; 30%). F. Most pharmacists got their 
information on NPS from the Internet/Web. N/A = no answer (1B); VM = very much (1E). 
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Figure 2. Significance of different aspects of NPS to pharmacists. We asked pharmacists to 
rate the importance of NPS-related information to improving their knowledge of NPS. The 
different types of information were rated from 1 (not significant) to 5 (very significant). The 
graph shows that pharmacists thought that adverse events, clinical warning signs and the 
desirable psychoactive effects were most relevant, with chemical characterisation 
considered relatively less significant. Values are medians. *P < 0.05 versus chemical 
characterisation. 
 
